Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | BCHE | P06276 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6616039 | 0.96 | TDP1 (0.51) | TDP1ALDH1A1KMT2ABCHEMAPT | |
| SCHEMBL6616637 | 0.88 | BCL2L1 (0.51) | TDP1ALDH1A1KMT2ABCHEMAPT | |
| SCHEMBL6616005 | 0.85 | PDPK1 (0.51) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8498365 | 0.82 | TDP1 (0.44) | TDP1ALDH1A1KMT2ABCHEMAPT | |
| SCHEMBL11742867 | 0.81 | TDP1 (0.59) | TDP1ALDH1A1KMT2ABCHEMAPT | |
| SCHEMBL6361049 | 0.80 | TDP1 (0.53) | TDP1ALDH1A1KMT2ABCHEMAPT | |
| SCHEMBL14522319 | 0.79 | DPP4 (0.43) | TDP1ALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL6621186 | 0.77 | PDE10A (0.51) | ALDH1A1SMN1; SMN2IDO1TDO2KDM4E | |
| SCHEMBL2601751 | 0.77 | ALDH1A1 (0.51) | TDP1ALDH1A1KMT2AMAPTHPGD | |
| SCHEMBL2601750 | 0.77 | ALDH1A1 (0.48) | TDP1ALDH1A1KMT2AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389721-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110136812-A1 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2286812-A1 | Solubilized topoisomerase poisons | Rutgers, The State University (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100240664-A1 | SOLUBILIZED TOPOISOMERASE POISON AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-09-23 | — | — | US | disclosed |
| US-7781587-B2 | antitumor; breast cancer; 8,9-Dimethoxy-2,3-methylenedioxy-5-[2-(N,N-dimethylamino)ethyl]-5H-dibenzo[c,h]1,6-naphthyridin-6-one | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2196205-A1 | Topoisomerase poisons | Rutgers, The State University (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-1465625-B1 | SOLUBILIZED TOPOISOMERASE POISONS | UNIV RUTGERS (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090239871-A1 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-09-24 | — | — | US | disclosed |
| US-7517883-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1453507-B1 | SOLUBILIZED TOPOISOMERASE POISON AGENTS | UNIV RUTGERS (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2003047505-A2 | TOPOISOMERASE POISON AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-06-12 | — | — | WO | disclosed |
| US-20030100560-A1 | Heterocyclic cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2003-05-29 | — | — | US | disclosed |
| WO-2003041653-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003041660-A2 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
| US-6486167-B1 | Heterocyclic cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2002-11-26 | — | — | US | disclosed |
| EP-1228045-A2 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032631-A2 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JEREY (US) | 2001-05-10 | — | — | WO | disclosed |
| US-6140328-A | FOR TREATING TUMOR | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1042294-A1 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031067-A1 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239871-A1 | SOLUBILIZED TOPOISOMERASE POISONS | TOP1, TOP2A, TOP2B | TDP1 4/4885ALDH1A1 3459/4885KMT2A 1606/4885 |
| US-20100240664-A1 | SOLUBILIZED TOPOISOMERASE POISON AGENTS | TOP1, TOP2A, TOP2B | TDP1 4/4885ALDH1A1 3664/4885KMT2A 1532/4885 |
| US-20110136812-A1 | SOLUBILIZED TOPOISOMERASE POISONS | TOP1, TOP2A, TOP2B | TDP1 4/4885ALDH1A1 3459/4885KMT2A 1606/4885 |
| US-20030100560-A1 | Heterocyclic cytotoxic agents | CCNA1, CCNE1, MCL1 | TDP1 563/4885ALDH1A1 114/4885KMT2A 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.